FLT3 inhibitors have transformed the treatment setting for FLT3-mutant acute myeloid leukemia, yet they have failed to resolve the persistent problem of relapse. While drugs like gilteritinib can produce clinically meaningful responses, resistance frequently develops, forcing researchers to identify the survival programs AML cells use to evade targeted therapies. A new study in Nature Cell Biology from Baylor College of Medicine identifies ferroptosis, an iron-dependent form of cell death, as a previously hidden vulnerability in these cancer cells.
The research centers on GPX4, a selenoprotein that shields cells from ferroptosis by preventing the buildup of lipid peroxides. AML cells with oncogenic FLT3 signaling appeared to depend on this pathway to maintain their resistance to ferroptosis. Using a reporter system for selenocysteine recoding, the team screened approved oncology drugs and found that tyrosine kinase inhibitors, particularly those with FLT3 activity, suppressed the translation of selenoproteins. Specifically, gilteritinib and ponatinib reduced GPX4 protein levels in FLT3-mutant AML cells, increased lipid peroxidation, and made the cells more susceptible to ferroptotic death.
Related: Personalized Treatment for Drug-Resistant TNBC Using Organoids
This was not simply a decrease in GPX4 gene expression. FLT3 inhibition disrupted selenocysteine recoding, the specialized translation process required to manufacture selenoproteins such as GPX4. That distinction places the vulnerability at the level of protein production rather than transcription, a detail that could inform future biomarker and drug-combination strategies.
Translational data from patient datasets supports the mechanism. FLT3-mutant samples resistant to gilteritinib showed higher expression of genes involved in selenoprotein production, including SECISBP2, SEPSECS, and RPL30. This suggests that leukemia cells may survive FLT3 inhibition by reinforcing the very pathway that protects them from ferroptosis. Mouse models backed up the finding; genetic deletion of Gpx4 delayed FLT3-ITD-driven leukemia and reduced leukemia-initiating populations, while normal hematopoietic progenitors were less dependent on GPX4. This differential reliance creates a potential therapeutic window, though directly targeting GPX4 or selenoprotein biology safely in patients remains a significant challenge.
Related: Weight Loss Alone May Not Stop Diabetes
The impact of vitamin E on treatment
The study also touches on a clinically sensitive issue: supplement use during cancer therapy. Vitamin E, an antioxidant known to suppress ferroptosis, markedly reduced the efficacy of gilteritinib in mouse models of FLT3-mutant AML. The supplement did not prevent FLT3 inhibition itself, but it weakened one downstream cell-death mechanism. While the authors note that clinical studies are needed to determine if a blanket recommendation for patients to avoid vitamin E during FLT3 inhibitor therapy is warranted, the finding highlights that “supportive” supplements are not always biologically neutral, especially when a therapy depends on oxidative or lipid-peroxidation stress to kill cancer cells.
For precision medicine, the research broadens the factors that may influence outcomes in FLT3-mutant AML. Future efforts will focus on determining whether these signals can help predict which patients respond to FLT3 inhibitors and which leukemias are already wired to survive them.
Leave a Reply